Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas

L. Castagna, S. Bramanti, S. Furst, L. Giordano, R. Crocchiolo, B. Sarina, E. Mauro, L. Morabito, R. Bouabdallah, D. Coso, M. Balzarotti, F. Broussais, J. El-Cheikh, C. C. Stella, E. Brusamolino, D. Blaise, A. Santoro

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count >20 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.

Original languageEnglish
Pages (from-to)1475-1480
Number of pages6
JournalBone Marrow Transplantation
Volume49
Issue number12
DOIs
Publication statusPublished - Dec 11 2014

Fingerprint

Lymphoma
Confidence Intervals
Transplants
Incidence
Tissue Donors
Recurrence
Hematopoietic Stem Cells
Transplantation
Conditioning (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. / Castagna, L.; Bramanti, S.; Furst, S.; Giordano, L.; Crocchiolo, R.; Sarina, B.; Mauro, E.; Morabito, L.; Bouabdallah, R.; Coso, D.; Balzarotti, M.; Broussais, F.; El-Cheikh, J.; Stella, C. C.; Brusamolino, E.; Blaise, D.; Santoro, A.

In: Bone Marrow Transplantation, Vol. 49, No. 12, 11.12.2014, p. 1475-1480.

Research output: Contribution to journalArticle

@article{efde6ba1c5aa42b0b9e4902a15cb38bf,
title = "Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas",
abstract = "Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87{\%} and transfusion independent plt count >20 × 10e9/L at 100 days was 87{\%}. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6{\%} (95{\%} confidence interval (CI): 12.9-38.3{\%}) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2{\%} (95{\%} CI: 0-12.4{\%}). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63{\%}. The relapse rate was 18.7{\%} (95{\%} CI: 7.6-29.8{\%}) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3{\%} (95{\%} CI: 5.9-26.8{\%}). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.",
author = "L. Castagna and S. Bramanti and S. Furst and L. Giordano and R. Crocchiolo and B. Sarina and E. Mauro and L. Morabito and R. Bouabdallah and D. Coso and M. Balzarotti and F. Broussais and J. El-Cheikh and Stella, {C. C.} and E. Brusamolino and D. Blaise and A. Santoro",
year = "2014",
month = "12",
day = "11",
doi = "10.1038/bmt.2014.197",
language = "English",
volume = "49",
pages = "1475--1480",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas

AU - Castagna, L.

AU - Bramanti, S.

AU - Furst, S.

AU - Giordano, L.

AU - Crocchiolo, R.

AU - Sarina, B.

AU - Mauro, E.

AU - Morabito, L.

AU - Bouabdallah, R.

AU - Coso, D.

AU - Balzarotti, M.

AU - Broussais, F.

AU - El-Cheikh, J.

AU - Stella, C. C.

AU - Brusamolino, E.

AU - Blaise, D.

AU - Santoro, A.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count >20 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.

AB - Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these donors, using T-repleted grafts, has recently been successfully reported. We report on 49 patients with refractory lymphoma who received T-repleted haploidentical SCT with a non-myeloablative regimen and post-transplant CY. The median time to recover ANC >0.5 × 10e9/L and transfusion independent plt count >20 × 10e9/L was 20 days (range 14-38) and 26 days (range 14-395). The probability to reach ANC >0.5 × 10e9/L at 30 days was 87% and transfusion independent plt count >20 × 10e9/L at 100 days was 87%. The cumulative incidence of grade 2-4 acute GVHD (aGVHD) was 25.6% (95% confidence interval (CI): 12.9-38.3%) and the cumulative incidence of chronic GVHD (cGVHD) was 5.2% (95% CI: 0-12.4%). The median follow-up is 20.6 months (range 12-54), and the projected 2-year OS and PFS were 71 and 63%. The relapse rate was 18.7% (95% CI: 7.6-29.8%) and the median time to relapse was 4.4 months (range 1.1-8.3). At 2 years, cumulative incidence of NRM was 16.3% (95% CI: 5.9-26.8%). T-repleted Haploidentical transplantation with post-infusion CY is a feasible and effective therapy in the poor prognosis of advanced lymphoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84927177380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927177380&partnerID=8YFLogxK

U2 - 10.1038/bmt.2014.197

DO - 10.1038/bmt.2014.197

M3 - Article

VL - 49

SP - 1475

EP - 1480

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 12

ER -